| Business Summary | | Cytogen
Corporation
is
a
biopharmaceutical
company
with
two
principal
lines
of
business,
proteomics
and
oncology.
The
Company
is
extending
its
expertise
in
antibodies
and
molecular
recognition
to
the
development
of
new
products
and
a
proteomics-driven
drug
discovery
platform.
The
Company
has
established
a
pipeline
of
product
candidates
based
upon
its
proprietary
antibody
and
its
exclusively
licensed
prostate
specific
membrane
antigen
(PSMA)
technologies.
The
Company
is
also
developing
a
proprietary
protein
pathway
database
as
a
drug
discovery
and
development
tool
for
the
pharmaceutical
and
biotechnology
industries. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CYTO
is
a
biopharmaceutical
company
with
two
principal
lines
of
business,
proteomics
and
oncology.
The
Company
also
develops
products
for
antibodies
and
molecular
recognition.
For
the
six
months
ended
6/30/01,
total
revenues
rose
15%
to
$5.8
million.
Net
loss
before
acct.
change
rose
39%
to
$5.7
million.
Results
reflect
the
release
of
new
products
and
the
establishment
of
an
in-house
oncology
sales
force,
offset
by
increased
development
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| James Grigsby, 58 Chairman | -- | -- | H. Joseph Reiser, Ph.D., 54 Pres,
CEO, Director | $606K | $1.0M | Lawrence Hoffman, 46 VP,
CFO | 131K | -- | Catherine Verna, 36 VP,
Gen. Counsel, Sec. | -- | -- | Deborah Kaminsky VP
of Sales and Marketing | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|